ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriatic arthritis and remission"

  • Abstract Number: 303 • 2019 ACR/ARP Annual Meeting

    Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission

    Johana Zacariaz Hereter1, Josefina Marin 2, Maria Laura Acosta Felquer 2, Martin Brom 3, Javier Rosa 4, Ricardo Garcia Monaco 1 and Enrique Soriano 5, 1Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, buenos aires, Ciudad Autonoma de Buenos Aires, Argentina, 3Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 4Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 5Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA). The aim of this study was to evaluate PDUS…
  • Abstract Number: 1535 • 2019 ACR/ARP Annual Meeting

    Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol

    Laura Coates1, Joseph Merola 2, Arthur Kavanaugh 3, Philip Mease 4, Owen Davies 5, Oscar Irvin-Sellers 6, Tommi Nurminen 7 and Désirée van der Heijde 8, 1University of Oxford, Oxford, United Kingdom, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3University of California, San Diego School of Medicine, La Jolla, CA, 4Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 5UCB Pharma, Slough, England, United Kingdom, 6UCB Pharma, Slough, UK, Slough, United Kingdom, 7UCB Pharma, Monheim, Germany, 8Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Several disease activity measures and thresholds have been recommended as psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate assessment tool is…
  • Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting

    Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate

    Leonieke van Mens1, Jet de Jong2, Inka Fluri1, Marleen van de Sande3, Michael Nurmohamed4, M.R. Kok5, Arno van Kuijk6 and Dominique Baeten2, 1Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, 5Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, 6Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands

    Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
  • Abstract Number: 2570 • 2018 ACR/ARHP Annual Meeting

    Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast

    Philip J. Mease1, Frank Behrens2, Dafna D Gladman3, Arthur Kavanaugh4, Michele Brunori5, Lichen Teng5, Benoit Guerette5, Rubén Queiro6 and Alexis Ogdie7, 1Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 2Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of California, San Diego, School of Medicine, La Jolla, CA, 5Celgene Corporation, Summit, NJ, 6Rheum-Derm Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The ability to predict responses to apremilast (APR) could impact treatment decisions. This post-hoc analysis was conducted to (1) assess the predictive values of…
  • Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting

    Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning

    Luminita Pricop1, Corine Gaillez2, Gregory Ligozio3, Xuan Zhu3 and David James3, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…
  • Abstract Number: 636 • 2018 ACR/ARHP Annual Meeting

    Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors

    Laure Gossec1,2, Paul Bergmans3, Kurt de Vlam4, Elisa Gremese5, Beatriz E. Joven6, Tatiana Korotaeva7, Michael Nurmohamed8,9, Petros Sfikakis10, Stefan Siebert11, Pavel Smirnov12, Elke Theander13 and Josef S. Smolen14, 1Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 2Rheumatology, Sorbonne Université, Paris, France, 3Biometrics, Janssen-Cilag B.V., Breda, Netherlands, 4University Hospitals Leuven, Leuven, Belgium, 5Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 6Hospital Universitario 12 de Octubre, Madrid, Spain, 7Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, 8Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 9Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, 10Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, 11Institute of Infection, Immunity and Inflammation, University of Glasgow, Cardiff, United Kingdom, 12Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation, 13Biometrics, Janssen-Cilag B.V., Solna, Sweden, 14Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

    Background/Purpose: The link between treatment recommendations for PsA (to aim for a state of remission or low disease activity (LDA))1,2 and patient-important outcomes has been…
  • Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting

    How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives

    Clémence Gorlier1, Deborah Puyraimond-Zemmour1, Laura C. Coates2, Ana-Maria Orbai3, Uta Kiltz4, Ying Ying Leung5, Penelope Palominos6, Juan D. Cañete7, Rossana Scrivo8, Andra Rodica Balanescu9, Emmanuelle Dernis10, Sandra Tälli11, Adeline Ruyssen-Witrand12, Martin Soubrier13, Sibel Zehra Aydın14, Lihi Eder15, Inna Gaydukova16, Ennio Lubrano17, Pascal Richette18, M. Elaine Husni19, Maarten de Wit20, Josef S. Smolen21 and Laure Gossec22, 1Sorbonne Université, PARIS, France, 2University of Oxford, Oxford, United Kingdom, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 6Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, 7Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, 8Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 9Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 10Service de Rhumatologie, CH du Mans, Le Mans, France, 11East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, 12Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, 13Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 14University of Ottawa, Ottawa, ON, Canada, 15Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 16North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, 17Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, 18Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, 19Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 20Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, 21Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 22Sorbonne Universités, Paris, France

    Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
  • Abstract Number: 643 • 2018 ACR/ARHP Annual Meeting

    Remission in Psoriatic Arthritis: Definition and Predictors

    Samar AlHarbi1, Justine Y. Ye2, Ker-Ai Lee3, Vinod Chandran2, Richard J. Cook3 and Dafna D Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: No validated definition of remission exists for psoriatic arthritis (PsA) to date. We previously identified 17.6% of our patients as having remission (no actively…
  • Abstract Number: 1607 • 2018 ACR/ARHP Annual Meeting

    Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast

    Laura C. Coates1, Philip J. Mease2, Frank Behrens3, Ana-Maria Orbai4, Alexis Ogdie5, Michele Brunori6, Lichen Teng6, Benoit Guerette6 and Josef S. Smolen7, 1University of Oxford, Oxford, United Kingdom, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5University of Pennsylvania, Philadelphia, PA, 6Celgene Corporation, Summit, NJ, 7Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

    Background/Purpose: Therapeutic targets for psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), measured by the Clinical Disease Activity Index…
  • Abstract Number: 2547 • 2017 ACR/ARHP Annual Meeting

    the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort

    Leonieke van Mens1, Arno van Kuijk2, Dominique Baeten1 and Laura C Coates3, 1AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, 2Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, 3LIRMM, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Recommendations on psoriatic arthritis (PsA) state that the target of treatment should be remission or inactive disease with an alternative target of minimal or…
  • Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting

    A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)

    Maria Laura Acosta Felquer1, Musaab Elmamoun2, Agnes Szentpetery3,4, Phil Gallagher5, Oliver FitzGerald6 and Enrique R. Soriano7, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 3Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 5St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, 6St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, 7Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…
  • Abstract Number: 1699 • 2016 ACR/ARHP Annual Meeting

    RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis

    Laura C. Coates1,2, William Tillett3,4, Theodore Pincus5, Arthur Kavanaugh6 and Philip S. Helliwell7, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 3Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 4Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5Rheumatology, Rush University Medical Center, Chicago, IL, 6Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 7NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose:  RAPID3 (routine assessment of patient index data) is a patient self-report index which is feasible in busy clinical settings to assess severity and change…
  • Abstract Number: 2766 • 2016 ACR/ARHP Annual Meeting

    The Predictive Value of Patient’s and Evaluator’s Global Assessment and Tender and Swollen Joint Count Differences on Treatment Efficacy in Psoriatic Arthritis: Data from a Longitudinal Multicenter Study

    Brigitte Michelsen1,2, Eirik K Kristianslund1, Hilde B Hammer3, Karen M Fagerli1, Elisabeth Lie1, Glenn Haugeberg4,5 and Tore K Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 3Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, 5Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway

    Background/Purpose: Discordance between patient’s and physician’s evaluation of disease activity may be challenging in psoriatic arthritis (PsA). The potential impact of such a difference on…
  • Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting

    Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis

    Barry J. Sheane1, Arane Thavaneswaran2, Dafna D. Gladman2 and Vinod Chandran2, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
  • Abstract Number: 2485 • 2013 ACR/ARHP Annual Meeting

    High Incidence Of Disease Recurrence After Discontinuation Of Disease Modifying Anti-Rheumatic Drug Treatment In Patients With Psoriatic Arthritis In Remission

    Elizabeth Araujo1, Stephanie Finzel1, Dominik A. Schreiber2, Matthias Englbrecht1, Axel J. Hueber3, Francesca Faustini3, Juergen Rech3 and Georg Schett1, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: In the era of modern anti-rheumatic therapy, it is now possible to contemplate the idea of clinical remission in patients with psoriatic arthritis (PsA).…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology